Biotechnology Innovation Organization· @IAmBiotech · X·· 23 天前AI 评分42
AI 导读
BIO 就 FDA 的加速 IND 试点项目发表评论，支持其滚动审评的构想，但提出担忧：要求必须有第三方研究合作伙伴，可能反而增加而非减少延误。https://Bio.News 有详细报道：https://bio.news/federal-policy/bio-applauds-efforts-targeting-early-drug-development-efficiency-provides-suggestions/
正文
BIO commented on FDA's Expedited IND Pilot Program, backing its rolling review concept but raising concerns that a required third-party research partner could add delays instead of removing them. https://Bio.News has the details: https://bio.news/federal-policy/bio-applauds-efforts-targeting-early-drug-development-efficiency-provides-suggestions/
来源：Biotechnology Innovation Organization · x.com